Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
What does it do?
Vaxcyte is a biotech company working on next-generation vaccines that protect against pneumococcal bacteria — the bugs behind deadly infections like pneumonia, meningitis, and sepsis. Think of it like this: existing vaccines on the market protect against roughly 20 strains of this bacteria, but Vaxcyte is building vaccines that cover 24 or even 31 strains, meaning broader protection for babies and adults. They haven't sold a single product yet — everything is still being tested in clinical trials. Their most advanced candidate, VAX-24, is designed for infants, while VAX-31 targets adults and older children.
Pneumococcal disease kills hundreds of thousands of people globally every year, and the current vaccine market is worth over $7 billion annually — dominated by Pfizer's Prevnar franchise. Vaxcyte is directly challenging that dominance with vaccines that cover more bacterial strains, which could translate into better protection and a massive share of a proven, high-value market. If their data holds up, they could force a significant shift in how doctors and health systems vaccinate both babies and adults.
How does it make money?
Vaxcyte currently makes zero revenue — this is a pre-commercial biotech, meaning it spends money developing drugs but hasn't earned a dollar from product sales yet. The company burns roughly $800 million per year funding its clinical trials, research teams, and operations. It stays alive by raising money from investors through stock offerings and sits on a cash pile it uses as a runway until (it hopes) a product gets approved. Once approved, it would sell vaccines directly to governments, health systems, and insurers — the same buyers who purchase billions of dollars of Pfizer's Prevnar today.
Why do investors care?
The core investment bet is simple: if VAX-24 or VAX-31 gets FDA approval and shows it protects against more strains than Pfizer's vaccine, hospitals and governments will switch — or at least split the market. Pfizer's Prevnar 20 generated roughly $6 billion in sales in 2023, so even capturing 20-30% of that market would make Vaxcyte enormously valuable. What has to go right: clinical trial data needs to show strong immune responses across all strains, the FDA has to approve the vaccine, and Vaxcyte needs to successfully build out commercial manufacturing and a sales operation from scratch.
Deep Dive
MemberA full investor briefing on Vaxcyte, Inc. — history, leadership, risks, and outlook.